Invasive disease-free survival and brain metastasis rates in patients treated with neoadjuvant chemotherapy with trastuzumab and pertuzumab Journal Article


Authors: Chew, S. M.; Ferraro, E.; Chen, Y.; Barrio, A. V.; Kelly, D.; Modi, S.; Seidman, A. D.; Wen, H.; Brogi, E.; Robson, M.; Dang, C. T.
Article Title: Invasive disease-free survival and brain metastasis rates in patients treated with neoadjuvant chemotherapy with trastuzumab and pertuzumab
Abstract: Patients with HER2(+) early breast cancer (EBC) receiving neoadjuvant systemic therapy (NAST) have poorer outcomes if they have residual disease (RD). We analyzed IDFS and brain metastasis (BM) rates in patients with HER2(+) EBC treated with NAST and report the outcomes of patients with HER2(−) RD. Patients with HER2(+) EBC who received NAST between 1 Jan 2019 and 31 Jan 2022 were reviewed. IDFS was defined as the time from surgery until first occurrence of invasive breast cancer recurrence, distant recurrence, or death from any cause. The total cohort was 594 patients. pCR (ypT0/isN0) was achieved in 325(55%) and RD was seen in 269(45%) patients. In 269 patients with RD, 45(17%) did not have HER2 retesting and were excluded. In the remaining 224 patients, 143(64%) were HER2(+) and 81(36%) were HER2(−). With a median follow up of 24 months, 8 patients developed BM at initial recurrence, 4/325(1.2%) with pCR and 4/143(2.8%) with HER2(+) RD. IDFS events occurred in 22/594(3%) patients; 14/269(5%) in RD and 8/325(2%) in pCR (p = 0.04). There was no difference in IDFS between 9/143(6%) patients with HER2(+) RD or 5/81(6%) with HER2(−) RD (p = 0.10). Patients with RD had higher IDFS events than those with pCR. In those with RD, 36% lost HER2(+) status; IDFS events appeared similar in those with HER2(+) RD versus those with HER2(−) RD. The BM events seen in those with RD and pCR highlights the need for more effective therapy in NAST and adjuvant setting to minimize BM risk. © The Author(s) 2024.
Keywords: immunohistochemistry; adult; human tissue; major clinical study; disease free survival; cancer staging; mastectomy; epidermal growth factor receptor 2; pathology; histology; gonadorelin; minimal residual disease; brain metastasis; neoadjuvant chemotherapy; trastuzumab; pertuzumab; breast-conserving surgery; trastuzumab emtansine; human epidermal growth factor receptor 2 positive breast cancer; human; male; female; article; postoperative pathology
Journal Title: npj Breast Cancer
Volume: 10
ISSN: 2374-4677
Publisher: Nature Publishing Group  
Date Published: 2024-10-28
Start Page: 96
Language: English
DOI: 10.1038/s41523-024-00631-9
PROVIDER: scopus
PMCID: PMC11519861
PUBMED: 39468041
DOI/URL:
Notes: Article -- MSK corresponding author is C. T. Dang -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Andrea Veronica Barrio
    134 Barrio
  2. Andrew D Seidman
    318 Seidman
  3. Mark E Robson
    676 Robson
  4. Chau Dang
    271 Dang
  5. Hannah Yong Wen
    301 Wen
  6. Shanu Modi
    265 Modi
  7. Edi Brogi
    515 Brogi
  8. Daniel William Kelly
    29 Kelly
  9. Emanuela Ferraro
    31 Ferraro
  10. Yuan Chen
    38 Chen